An Expanded Access Program for Efgartigimod Treatment in

Recruiting

99 years or below

All

1 participants needed

1 Location

Brief description of study

This study provides patients with generalized myasthenia gravis (gMG), who are ineligible to participate in a clinical trial, access to efgartigimod treatment before regulatory approval. This expanded access protocol applies to patients with gMG who are not enrolled in an ongoing clinical trial. Enrolled patients will receive cycles of efgartigimod IV 10 mg/kg infused once weekly for 4 infusions.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 12 May 2021. Study ID: 848793

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

An Expanded Access Program for Efgartigimod Treatment in Patients With Generalized Myasthenia Gravis

Brief description of study

Eligibility of study

Find a site

Interested in the study